Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia. We utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection. As part of the CSL Group, we have been producing influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.
View Top Employees from SeqirusWebsite | http://www.seqirus.com |
Employees | 2,051 (2,051 on RocketReach) |
Founded | 1916 |
Category | Pharmaceutical Manufacturing, Vaccines, Antivenoms, Contract logistics, In-licensing, Immunohaematology, Pharmaceuticals |
Web Rank | 2 Million |
Keywords | seqirus, sequiris, csl liverpool, seqirus inc. careers jobs, seqirus inc. |
Looking for a particular Seqirus employee's phone or email?
Joaquin Mould is the Global Pricing and Health Economics Director of Seqirus.
2,051 people are employed at Seqirus.